U.S. markets close in 51 minutes
  • S&P 500

    3,994.08
    -77.62 (-1.91%)
     
  • Dow 30

    33,933.21
    -496.67 (-1.44%)
     
  • Nasdaq

    11,212.27
    -249.22 (-2.17%)
     
  • Russell 2000

    1,837.51
    -55.33 (-2.92%)
     
  • Crude Oil

    77.39
    -2.59 (-3.24%)
     
  • Gold

    1,780.50
    -29.10 (-1.61%)
     
  • Silver

    22.40
    -0.85 (-3.68%)
     
  • EUR/USD

    1.0499
    -0.0032 (-0.30%)
     
  • 10-Yr Bond

    3.6010
    +0.0950 (+2.71%)
     
  • GBP/USD

    1.2181
    -0.0115 (-0.93%)
     
  • USD/JPY

    136.6320
    +2.3610 (+1.76%)
     
  • BTC-USD

    16,944.12
    -152.58 (-0.89%)
     
  • CMC Crypto 200

    399.98
    -11.23 (-2.73%)
     
  • FTSE 100

    7,567.54
    +11.31 (+0.15%)
     
  • Nikkei 225

    27,820.40
    +42.50 (+0.15%)
     

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc

DUBLIN, Ireland, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one (1) new employee to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan. The award was granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the employee’s first day of employment with Avadel and the remainder vesting in equal monthly installments for three years thereafter, subject to the employee’s continued service with Avadel on each such vesting date. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, LUMRYZ™, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Gabriella Greig
Real Chemistry
ggreig@realchemistry.com
(203) 249-2688